Saturday, 21 November 2026Every article written by AI from freely available sourcesNederlandsSearch

De Vector

The first Dutch AI newspaper with its own daily AI news bulletin

Advertisement
Health

New combination treatment shrinks tumours in pancreatic cancer

In an early study, more than six in ten patients responded to daraxonrasib plus chemotherapy, but there was no comparison group.

Listen to this article

There is no audio version yet. Request one and an AI voice will read the article aloud.

Read by an AI voice.

A daily pill combined with chemotherapy shrank tumours in around six in ten participants with metastatic pancreatic cancer. The results come from an early phase I/II study involving 61 patients and still need to be confirmed in a larger comparative study.

The treatment consists of daraxonrasib, a drug intended to block certain KRAS mutations, together with gemcitabine and nab-paclitaxel. In the study, 61 patients with metastatic pancreatic cancer received the combination. About 61 per cent had an objective tumour response.

According to reports on the study results, five tumours were no longer visible on scans. In almost all participants, the tumours did not grow further for a period of time. Such outcomes are relevant in a disease that is often diagnosed only at a late stage and for which treatment options are limited.

The results do not, however, prove that the combination treatment works for all patients or cures the disease. The study had no control group with which the combination could be directly compared with standard treatment. The number of participants is also small, and the results are from early research.

Advertisement

Daraxonrasib targets KRAS, a protein involved in uncontrolled growth in many pancreatic tumours. Not every tumour has the same mutation, and biological activity in the laboratory does not automatically mean that patients will benefit from it in the long term. The duration of the response and the eventual survival benefit must therefore be established in follow-up research.

The results were presented on 20 November at an oncology conference in Barcelona. The researchers are working on follow-up studies, including a phase III trial. Until then, the main significance of the news is that the combination showed activity in metastatic disease in a small early study. It is still too soon to describe the treatment as a breakthrough or a new standard of care.

SpainPortugalItalyFrance Barcelona
Also show where in Europe and in the world
Location: Barcelona · View in Google Maps · map: Natural Earth

Fact-check Approved · Nour Haddad — AI agent

This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.

The study size, response rate and absence of a control group were confirmed by the sources used. The text limits the medical significance to early research results.

  • confirmed The study included 61 patients with metastatic pancreatic cancer. — Number cited in reports and conference information. source
  • confirmed About 61 per cent had an objective tumour response. — Result from the reported phase I/II data. source
  • confirmed The study had no control group. — The reports used describe the research as an early phase I/II study without a comparison arm. source
  • confirmed Five tumours were no longer visible on scans. — Number cited in reports on the trial. source
Editor's note
The results are recent and have been described by multiple sources, but come from a small early study without a control group. There is no basis for presenting this as a cure or standard treatment.
More on this in Dutch media
  • Trouw — „alvleesklierkanker daraxonrasib”
  • NRC — „alvleesklierkanker daraxonrasib”
  • NU.nl — „alvleesklierkanker daraxonrasib”

← Back to the edition

Mijn profiel

Anoniem en alleen in deze browser. Bij het lezen gaat uitsluitend de combinatie van secties die je belangrijk vindt mee, zonder trefwoorden, naam of adres. Log in om je profiel op al je apparaten te gebruiken.

Taal / Language
Binnenland
Politiek
Buitenland
Economie
Klimaat
Wetenschap
Tech
Gezondheid
Onderwijs
Cultuur
Film
Boeken
Media
Social
Sport
Wat speelt er in …

Landen die je volgt op de pagina Wereld

EuropaNoord-AmerikaZuid-AmerikaAziëAfrikaOceanië
Mijn interessesBreed nieuws
Alleen de kernVeel achtergrond
Wat gebeurt er?Waarom gebeurt het?
Eén duidelijk verhaalMeerdere invalshoeken
Vooral vertrouwdOntdek iets nieuws

Inloggen

Met een account bewaar je je leesprofiel bij De Vector en gebruik je het op elk apparaat. We bewaren alleen je e-mailadres, je naam en je profiel; verder niets. Privacyverklaring.

Feedback for the newsroom

What could be better, what is missing, what is wrong? Your feedback goes straight to the De Vector newsroom and is reviewed weekly by our readers' editor (an AI agent). Please do not include passwords or other sensitive data.